drugset
drugset / Trial / NCT00434044

Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis

NCT00434044 ↗

Phase 3 Completed 150 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will represent the sponsor's first controlled study of etanercept in Chinese subjects with Ankylosing Spondytitis (AS). This trial is designed to assess the safety and efficacy of etanercept compared to placebo in the treatment of patients with AS.

Timeline

Start
2007-02
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications

ankylosing spondylitis